@article{MTMT:34852892,
	title = {Long-term outcomes after endoscopic removal of malignant colorectal polyps. Results from a 10-year cohort},
	url = {https://m2.mtmt.hu/api/publication/34852892},
	author = {Fábián, Anna and Bor, Renáta and Vasas, Béla and Szűcs, Mónika and Tóth, Tibor and Bősze, Zsófia and Szántó, Kata Judit and Bacsur, Péter and Bálint, Anita and Farkas, Bernadett and Farkas, Klaudia and Milassin, Ágnes and Rutka, Mariann and Resál, Tamás and Molnár, Tamás and Szepes, Zoltán},
	doi = {10.4253/wjge.v16.i4.193},
	journal-iso = {WORLD J GASTROINTEST ENDOSC},
	journal = {WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY},
	volume = {16},
	unique-id = {34852892},
	abstract = {Choosing an optimal post-polypectomy management strategy of malignant colorectal polyps is challenging, and evidence regarding a surveillance-only strategy is limited.To evaluate long-term outcomes after endoscopic removal of malignant colorectal polyps.A single-center retrospective cohort study was conducted to evaluate outcomes after endoscopic removal of malignant colorectal polyps between 2010 and 2020. Residual disease rate and nodal metastases after secondary surgery and local and distant recurrence rate for those with at least 1 year of follow-up were investigated. Event rates for categorical variables and means for continuous variables with 95% confidence intervals were calculated, and Fisher's exact test and Mann-Whitney test were performed. Potential risk factors of adverse outcomes were determined with univariate and multivariate logistic regression models.In total, 135 lesions (mean size: 22.1 mm; location: 42% rectal) from 129 patients (mean age: 67.7 years; 56% male) were enrolled. The proportion of pedunculated and non-pedunculated lesions was similar, with en bloc resection in 82% and 47% of lesions, respectively. Tumor differentiation, distance from resection margins, depth of submucosal invasion, lymphovascular invasion, and budding were reported at 89.6%, 45.2%, 58.5%, 31.9%, and 25.2%, respectively. Residual tumor was found in 10 patients, and nodal metastasis was found in 4 of 41 patients who underwent secondary surgical resection. Univariate analysis identified piecemeal resection as a risk factor for residual malignancy (odds ratio: 1.74; P = 0.042). At least 1 year of follow-up was available for 117 lesions from 111 patients (mean follow-up period: 5.59 years). Overall, 54%, 30%, 30%, 11%, and 16% of patients presented at the 1-year, 3-year, 5-year, 7-year, and 9-10-year surveillance examinations. Adverse outcomes occurred in 9.0% (local recurrence and dissemination in 4 patients and 9 patients, respectively), with no difference between patients undergoing secondary surgery and surveillance only.Reporting of histological features and adherence to surveillance colonoscopy needs improvement. Long-term adverse outcome rates might be higher than previously reported, irrespective of whether secondary surgery was performed.},
	keywords = {LONG-TERM; SURVEILLANCE; OUTCOMES; endoscopic removal; Malignant colorectal polyps; T1 tumor},
	year = {2024},
	eissn = {1948-5190},
	pages = {193-205},
	orcid-numbers = {Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szűcs, Mónika/0000-0002-8791-9452; Szántó, Kata Judit/0000-0003-0749-5061; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Farkas, Klaudia/0000-0003-0599-182X; Milassin, Ágnes/0000-0001-6902-8915; Rutka, Mariann/0000-0003-2360-7836; Resál, Tamás/0000-0002-3842-9094; Molnár, Tamás/0000-0002-4913-7599; Szepes, Zoltán/0000-0002-9466-8719}
}

@article{MTMT:34538603,
	title = {P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases},
	url = {https://m2.mtmt.hu/api/publication/34538603},
	author = {Jójárt, Boldizsár and Resál, Tamás and Kata, Diána and Molnár, Tünde and Bacsur, Péter and Szabó, Viktória and Varga, Árpád and Szántó, Kata Judit and Pallagi, Petra and Földesi, Imre and Molnár, Tamás and Maléth, József and Farkas, Klaudia},
	doi = {10.1093/ecco-jcc/jjad212.0551},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34538603},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {i869-i869},
	orcid-numbers = {Jójárt, Boldizsár/0000-0002-2764-3925; Resál, Tamás/0000-0002-3842-9094; Kata, Diána/0000-0002-4432-9380; Molnár, Tünde/0000-0002-6842-6521; Bacsur, Péter/0000-0002-8534-0068; Szabó, Viktória/0000-0001-6547-9102; Varga, Árpád/0000-0002-2379-139X; Szántó, Kata Judit/0000-0003-0749-5061; Pallagi, Petra/0000-0001-8906-0840; Földesi, Imre/0000-0002-3329-8136; Molnár, Tamás/0000-0002-4913-7599; Maléth, József/0000-0001-5768-3090; Farkas, Klaudia/0000-0003-0599-182X}
}

@article{MTMT:34167015,
	title = {Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases},
	url = {https://m2.mtmt.hu/api/publication/34167015},
	author = {Jójárt, Boldizsár and Resál, Tamás and Kata, Diána and Molnár, Tünde and Bacsur, Péter and Szabó, Viktória and Varga, Árpád and Szántó, Kata Judit and Pallagi, Petra and Földesi, Imre and Molnár, Tamás and Maléth, József and Farkas, Klaudia},
	doi = {10.1093/ecco-jcc/jjad160},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34167015},
	issn = {1873-9946},
	abstract = {Crohn's disease and ulcerative colitis require lifelong treatment and patient monitoring. Current biomarkers have several limitations, therefore, there is an unmet need to identify novel biomarkers in inflammatory bowel disease (IBD). Previously, the role of plasminogen activator inhibitor 1 (PAI-1) was established in the pathogenesis of IBD and suggested as a potential biomarker. Therefore, we aimed to comprehensively analyze the selectivity of PAI-1 in IBD, its correlation with the disease activity, and its potential to predict therapeutic response.Blood, colon biopsy, organoid cultures (OC), and faecal samples were used from active and inactive IBD patients and control subjects. Serpin E1 gene expressions and PAI-1 protein levels and localization in serum, biopsy, and fecal samples were evaluated by qRT-PCR, ELISA, and immunostaining, respectively.The study population comprised 132 IBD patients (56 CD and 76 UC) and 40 non-IBD patients. We demonstrated that the serum, mucosal, and faecal PAI-1 concentration is elevated in IBD patients, showing clinical and endoscopic activity. In responders (decrease of eMayo≥3 in UC; or SES-CD>50% in CD), the initial PAI-1 level decreased significantly upon successful therapy. OCs derived from active IBD patients produced higher concentrations of PAI-1 than the controls, suggesting that epithelial cells could be a source of PAI-1. Moreover, faecal PAI-1 selectively increases in active IBD but not other organic gastrointestinal diseases.The serum, mucosal, and faecal PAI-1 concentration correlates with the disease activity and therapeutic response in IBD, suggesting that PAI-1 could be utilized as a novel non-invasive, disease-specific faecal biomarker in the patient follow-up.},
	keywords = {Inflammatory bowel disease; PAI-1; faecal marker},
	year = {2024},
	eissn = {1876-4479},
	pages = {392-405},
	orcid-numbers = {Jójárt, Boldizsár/0000-0002-2764-3925; Resál, Tamás/0000-0002-3842-9094; Kata, Diána/0000-0002-4432-9380; Molnár, Tünde/0000-0002-6842-6521; Bacsur, Péter/0000-0002-8534-0068; Szabó, Viktória/0000-0001-6547-9102; Varga, Árpád/0000-0002-2379-139X; Szántó, Kata Judit/0000-0003-0749-5061; Pallagi, Petra/0000-0001-8906-0840; Földesi, Imre/0000-0002-3329-8136; Molnár, Tamás/0000-0002-4913-7599; Maléth, József/0000-0001-5768-3090; Farkas, Klaudia/0000-0003-0599-182X}
}

@article{MTMT:34593890,
	title = {LDN-051 a novel fecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases – results of a phase 2 clinical trial},
	url = {https://m2.mtmt.hu/api/publication/34593890},
	author = {Jójárt, Boldizsár and Resál, Tamás and Kata, Diána and Molnár, Tünde and Bacsur, Péter and Szabó, Viktória and Varga, Árpád and Szántó, Kata Judit and Földesi, Imre and Molnár, Tamás and Maléth, József and Farkas, Klaudia},
	journal-iso = {UEG JOURNAL},
	journal = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
	volume = {11},
	unique-id = {34593890},
	issn = {2050-6406},
	year = {2023},
	eissn = {2050-6414},
	pages = {291-292},
	orcid-numbers = {Jójárt, Boldizsár/0000-0002-2764-3925; Resál, Tamás/0000-0002-3842-9094; Kata, Diána/0000-0002-4432-9380; Molnár, Tünde/0000-0002-6842-6521; Bacsur, Péter/0000-0002-8534-0068; Szabó, Viktória/0000-0001-6547-9102; Varga, Árpád/0000-0002-2379-139X; Szántó, Kata Judit/0000-0003-0749-5061; Földesi, Imre/0000-0002-3329-8136; Molnár, Tamás/0000-0002-4913-7599; Maléth, József/0000-0001-5768-3090; Farkas, Klaudia/0000-0003-0599-182X}
}

@mastersthesis{MTMT:34113040,
	title = {Crucial steps for treatment optimization and decision making in inflammatory bowel disease management [A terápia optimalizálását és a döntéshozatalt befolyásoló tényezők a gyulladásos bélbetegségek kezelése során]},
	url = {https://m2.mtmt.hu/api/publication/34113040},
	author = {Szántó, Kata Judit},
	doi = {10.14232/phd.11527},
	publisher = {Universití of Szeged},
	unique-id = {34113040},
	year = {2023},
	orcid-numbers = {Szántó, Kata Judit/0000-0003-0749-5061}
}

@article{MTMT:34071361,
	title = {Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.},
	url = {https://m2.mtmt.hu/api/publication/34071361},
	author = {Resál, Tamás and Bacsur, Péter and Horváth, Miklós and Szántó, Kata Judit and Rutka, Mariann and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Fekete, János Tibor and Farkas, Klaudia and Miheller, Pál and Molnár, Tamás},
	doi = {10.1177/17562848231183529},
	journal-iso = {THER ADV GASTROENTER},
	journal = {THERAPEUTIC ADVANCES IN GASTROENTEROLOGY},
	volume = {16},
	unique-id = {34071361},
	issn = {1756-283X},
	abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has complicated the management of inflammatory bowel diseases (IBD).This study aimed to assess the efficacy of different anti-SARS-CoV-2 vaccines under different treatments in IBD patients and identify predictive factors associated with lower serological response, including anti-tumor necrosis factor (anti-TNF) drug levels.A prospective, double-center study of IBD patients was conducted following messenger ribonucleotide acid (mRNA) and non-mRNA anti-SARS-CoV-2 vaccination.Healthy control (HC) patients were enrolled to reduce bias. Baseline and control samples were obtained 14 days after the second dose to assess the impact of conventional and biological treatments. Clinical and biochemical activity, serological response level, and anti-TNF drug levels were measured.This study included 199 IBD (mean age, 40.9 ± 12.72 years) and 77 HC participants (mean age, 50.3 ± 12.36 years). Most patients (76.9%) and all HCs received mRNA vaccines. Half of the IBD patients were on biological treatment (anti-TNF 68.7%). Biological and thiopurine combined immunomodulation and biological treatment were associated with lower serological response (p < 0.001), and mRNA vaccination promoted better antibody levels (p < 0.001). Higher adalimumab levels caused lower serological response (p = 0.006). W8 persistence of anti-SARS-CoV-2 level was equal in IBD and HC groups. Vaccination did not aggravate clinical disease activity (p = 0.65).Anti-SARS-CoV-2 vaccination is considerably efficacious in IBD patients, with mRNA vaccines promoting better antibody levels. The negative impact of combined biological treatment, especially with high adalimumab drug levels, on serological response to vaccination should be considered. Although midterm durability of vaccination is encouraging, more data are needed to expand the existing understanding on this issue.},
	keywords = {IBD; vaccination; persistence; Durability; Anti-TNF; COVID-19},
	year = {2023},
	eissn = {1756-2848},
	orcid-numbers = {Resál, Tamás/0000-0002-3842-9094; Bacsur, Péter/0000-0002-8534-0068; Horváth, Miklós/0000-0003-0661-3388; Szántó, Kata Judit/0000-0003-0749-5061; Rutka, Mariann/0000-0003-2360-7836; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Fekete, János Tibor/0000-0002-6672-6563; Farkas, Klaudia/0000-0003-0599-182X; Miheller, Pál/0000-0003-3448-4333; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34014839,
	title = {Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls},
	url = {https://m2.mtmt.hu/api/publication/34014839},
	author = {Bacsur, Péter and Rutka, Mariann and Asbóth, András and Resál, Tamás and Szántó, Kata Judit and Jójárt, Boldizsár and Bálint, Anita and Ari, Eszter and Ajibola, Walliyulahi and Kintses, Bálint and Fehér, Tamás and Pigniczki , Daniella and Bor, Renáta and Fábián, Anna and Maléth, József and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás},
	doi = {10.1177/17562848231174298},
	journal-iso = {THER ADV GASTROENTER},
	journal = {THERAPEUTIC ADVANCES IN GASTROENTEROLOGY},
	volume = {16},
	unique-id = {34014839},
	issn = {1756-283X},
	year = {2023},
	eissn = {1756-2848},
	orcid-numbers = {Bacsur, Péter/0000-0002-8534-0068; Rutka, Mariann/0000-0003-2360-7836; Resál, Tamás/0000-0002-3842-9094; Szántó, Kata Judit/0000-0003-0749-5061; Jójárt, Boldizsár/0000-0002-2764-3925; Bálint, Anita/0000-0002-3624-896X; Ari, Eszter/0000-0001-7774-1067; Fehér, Tamás/0000-0001-9318-3640; Pigniczki , Daniella/0000-0001-6395-2576; Bor, Renáta/0000-0001-9393-5240; Fábián, Anna/0000-0002-0824-7476; Maléth, József/0000-0001-5768-3090; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34012213,
	title = {Plasminogen activator inhibitor 1 - a novel potential biomarker in inflammatory bowel diseases},
	url = {https://m2.mtmt.hu/api/publication/34012213},
	author = {Jójárt, Boldizsár and Resál, Tamás and Kata, Diána and Molnár, Tünde and Bacsur, Péter and Szabó, Viktória and Varga, Árpád and Szántó, Kata Judit and Földesi, Imre and Molnár, Tamás and Maléth, József and Farkas, Klaudia},
	journal-iso = {CENT EUR J GASTRO HEPATOL},
	journal = {CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE},
	volume = {9},
	unique-id = {34012213},
	year = {2023},
	eissn = {2415-9107},
	pages = {85-85},
	orcid-numbers = {Jójárt, Boldizsár/0000-0002-2764-3925; Resál, Tamás/0000-0002-3842-9094; Kata, Diána/0000-0002-4432-9380; Molnár, Tünde/0000-0002-6842-6521; Bacsur, Péter/0000-0002-8534-0068; Szabó, Viktória/0000-0001-6547-9102; Varga, Árpád/0000-0002-2379-139X; Szántó, Kata Judit/0000-0003-0749-5061; Földesi, Imre/0000-0002-3329-8136; Molnár, Tamás/0000-0002-4913-7599; Maléth, József/0000-0001-5768-3090; Farkas, Klaudia/0000-0003-0599-182X}
}

@article{MTMT:33697762,
	title = {Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone},
	url = {https://m2.mtmt.hu/api/publication/33697762},
	author = {Resál, Tamás and Mangó, Katalin and Bacsur, Péter and Szántó, Kata Judit and Pigniczki , Daniella and Keresztes, Csilla and Rutka, Mariann and Bálint, Anita and Milassin, Ágnes and Bor, Renáta and Fábián, Anna and Szepes, Zoltán and Farkas, Klaudia and Monostory, Katalin and Molnár, Tamás},
	doi = {10.1080/14740338.2023.2181336},
	journal-iso = {EXPERT OPIN DRUG SAF},
	journal = {EXPERT OPINION ON DRUG SAFETY},
	volume = {22},
	unique-id = {33697762},
	issn = {1474-0338},
	year = {2023},
	eissn = {1744-764X},
	pages = {517-524},
	orcid-numbers = {Resál, Tamás/0000-0002-3842-9094; Bacsur, Péter/0000-0002-8534-0068; Szántó, Kata Judit/0000-0003-0749-5061; Pigniczki , Daniella/0000-0001-6395-2576; Rutka, Mariann/0000-0003-2360-7836; Bálint, Anita/0000-0002-3624-896X; Milassin, Ágnes/0000-0001-6902-8915; Bor, Renáta/0000-0001-9393-5240; Fábián, Anna/0000-0002-0824-7476; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:33667439,
	title = {Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19},
	url = {https://m2.mtmt.hu/api/publication/33667439},
	author = {Dávid, Anett and Szántó, Kata Judit and Fábián, Anna and Resál, Tamás and Farkas, Klaudia and Hallgató, Emese and Miheller, Pál and Sarlós, Patrícia and Molnár, Tamás and Rafael, Beatrix},
	doi = {10.5114/pg.2023.131398},
	journal-iso = {PRZ GASTROENTEROL},
	journal = {PRZEGLAD GASTROENTEROLOGICZNY},
	volume = {18},
	unique-id = {33667439},
	issn = {1895-5770},
	year = {2023},
	eissn = {1897-4317},
	pages = {334-343},
	orcid-numbers = {Dávid, Anett/0000-0002-0459-6249; Szántó, Kata Judit/0000-0003-0749-5061; Fábián, Anna/0000-0002-0824-7476; Resál, Tamás/0000-0002-3842-9094; Farkas, Klaudia/0000-0003-0599-182X; Miheller, Pál/0000-0003-3448-4333; Sarlós, Patrícia/0000-0002-5086-9455; Molnár, Tamás/0000-0002-4913-7599; Rafael, Beatrix/0000-0002-9272-2603}
}